Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.7957
37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
BIOVF Price Targets Summary
Swedish Orphan Biovitrum AB (publ)
According to Wall Street analysts, the average 1-year price target for
BIOVF
is 41.31 USD
with a low forecast of 32.68 USD and a high forecast of 51.67 USD.
Revenue
Forecast
Revenue Estimate
Swedish Orphan Biovitrum AB (publ)
For the last 13 years the
compound annual growth rate for
Swedish Orphan Biovitrum AB (publ)'s revenue is
22%.
The projected
CAGR
for the next 4 years is
11%.
Net Income
Forecast
Net Income Estimate
Swedish Orphan Biovitrum AB (publ)
For the last 13 years the
compound annual growth rate for
Swedish Orphan Biovitrum AB (publ)'s net income is
51%.
The projected
CAGR
for the next 4 years is
25%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BIOVF's stock price target?
Price Target
41.31
USD
According to Wall Street analysts, the average 1-year price target for
BIOVF
is 41.31 USD
with a low forecast of 32.68 USD and a high forecast of 51.67 USD.
What is Swedish Orphan Biovitrum AB (publ)'s Revenue forecast?
Projected CAGR
11%
For the last 13 years the
compound annual growth rate for
Swedish Orphan Biovitrum AB (publ)'s revenue is
22%.
The projected
CAGR
for the next 4 years is
11%.
What is Swedish Orphan Biovitrum AB (publ)'s Operating Income forecast?
Projected CAGR
16%
The
compound annual growth rate
of Swedish Orphan Biovitrum AB (publ)'s operating income for the next 4 years is
16%.
What is Swedish Orphan Biovitrum AB (publ)'s Net Income forecast?
Projected CAGR
25%
For the last 13 years the
compound annual growth rate for
Swedish Orphan Biovitrum AB (publ)'s net income is
51%.
The projected
CAGR
for the next 4 years is
25%.
